Neutralization of pro-inflammatory monocytes by targeting TLR2 dimerization ameliorates colitis

Liraz Shmuel-Galia†, Tegeist Aychek‡, Avner Fink§, Ziv Porat∥, Batya Zarmi¶, Biana Bernshtein*, Ori Brenner#, Steffen Jung* & Yechiel Shai**

Abstract

Monocytes have emerged as critical driving force of acute inflammation. Here, we show that inhibition of Toll-like receptor 2 (TLR2) dimerization by a TLR2 transmembrane peptide (TLR2-p) ameliorated DSS-induced colitis by interfering specifically with the activation of Ly6C+ monocytes without affecting their recruitment to the colon. We report that TLR2-p directly interacts with TLR2 within the membrane, leading to inhibition of TLR2–TLR6/1 assembly induced by natural ligands. This was associated with decreased levels of extracellular signal-regulated kinases (ERK) signaling and reduced secretion of pro-inflammatory cytokines, such as interleukin (IL)-1β. This provides insights into the essential role of TLR2 dimerization in the activation of pathogenic pro-inflammatory Ly6C+ monocytes and suggests that inhibition of this aggregation by TLR2-p might have therapeutic potential in the treatment of acute gut inflammation.

Keywords colitis; monocytes; TLR2; Toll-like receptor

Subject Categories Immunology

DOI 10.15252/embr.201592649 | Received 23 July 2015 | Revised 13 January 2016 | Accepted 15 January 2016 | Published online 16 February 2016

The EMBO Journal (2016) 35: 685–698

Introduction

Intestinal immune cells play a fundamental role in the maintenance of gut homeostasis and gut defense against pathogen invasion (Kabat et al., 2014). Gut health relies on the establishment of quiescent coexistence of immune cells and the commensal bacteria. Dysregulation of the response toward commensals results in the development of inflammatory bowel disease (IBD) (Casellas et al., 1998; Strober et al., 2002; Cho, 2008; Sun et al., 2011; Zhang & Li, 2014). Human IBD includes Crohn’s disease (CD) and ulcerative colitis (UC), which differ in the location of the maladies.

Ulcerative colitis is characterized by pronounced inflammation of the intestinal mucosa, generally restricted to the colon. Until recently, UC pathogenesis was thought to be largely driven by an aggressive adaptive immune response against luminal bacterial antigens. However, more recent studies and genomewide association studies (GWAS) suggest uncontrolled reactivity of innate immune cells as prime cause of chronic inflammation in UC (Jostins et al., 2012; Corridoni et al., 2014). Specifically, mouse UC models have highlighted a prominent influx of Ly6C+ blood monocytes into the tissue. In the healthy lamina propria, these cells maintain the intestinal macrophage compartment (Varol et al., 2009; Bain et al., 2014) and differentiate into quiescent intestinal macrophages (Rivollier et al., 2012; Zigmond et al., 2012). Under pathological conditions however, the same cells fail to be appeased, but respond to bacterial stimuli by acquiring pro-inflammatory activities and, as a result, actively promote disease (Rivollier et al., 2012; Zigmond et al., 2012).

Toll-like receptors (TLR) are membrane pattern recognition receptors (PRRs) that recognize a wide range of microbial products (Kang & Lee, 2011). TLR activation by certain ligands induces the critical formation of TLR dimers with unique specificities (Botos et al., 2011). Upon binding to di- and tri-acylated lipoproteins, TLR2 dimerizes, for instance, with TLR6 and TLR1, respectively (Ozinsky et al., 2000; Takeuchi et al., 2002). TLR dimerization is coordinated through ligand binding to the extracellular domain of one receptor, leading to their lateral movement toward the partner molecule resulting in conformational changes throughout the proteins (Akira & Takeda, 2004). Once in the complex, TLR2 interacts with coreceptors allowing recruitment of adaptor proteins, such as MyD88 or TRIF (Deguine & Barton, 2014; Narayanan & Park, 2015) and stimulating signaling pathways (Kawai & Akira, 2011), which ultimately induce a range of inflammatory cytokines and chemokines (Kaisho & Akira, 2006; Fukata & Arditi, 2013).

During acute and chronic inflammation, TLR engagement by commensal-derived products triggers the production of pro-inflammatory agents. The latter notion is supported by abounding evidence of TLR over-expression and activity in tissues obtained from IBD patients (Hausmann et al., 2002; Canto et al., 2006).

1 Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel
2 Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
3 Department of Biological Services, The Weizmann Institute of Science, Rehovot, Israel
4 Department of Veterinary Resources, The Weizmann Institute of Science, Rehovot, Israel
*Corresponding author. Tel: +972 8 934 3278; Fax: +972 8 934 4141; E-mail: s.jung@weizmann.ac.il
**Corresponding author. Tel: +972 8 934 2711; Fax: +972 8 934 4112; E-mail: yechiel.shai@weizmann.ac.il
†These authors contributed equally to the work
Specifically, TLR2 was shown to be significantly more active in peripheral mononuclear cells from UC patients than those obtained from healthy individuals (Toiyama et al., 2006; Frolova et al., 2008). Moreover, the dimerization of TLR2 with TLR6 was shown to play an important role in colitis, as compared to TLR2–TLR1 dimerization (Morgan et al., 2014). The critical role of TLR2–TLR6 dimers in disease development is further supported by the finding that TLR6-deficient mice are resistant to colitis (Morgan et al., 2014). Collectively, these results highlight the importance of TLR2 and particularly its assembly with TLR6 in UC development.

Ly6C\(^{hi}\) monocytes that enter inflamed gut tissue upregulate expression of TLR2, TLR6, and NOD2 (Zigmond et al., 2012) that are involved in the induction of pro-inflammatory cytokines, such as IL-6, IL-23, and IL-1β (Zigmond et al., 2012; Neurath, 2014).

Here, we investigated the role of TLR2 signaling in monocytes in the development of acute murine colitis. We show that TLR2 heterodimerization plays a fundamental role in the activation of the pro-inflammatory potential of Ly6C\(^{hi}\) monocytes. Specifically, inhibition of TLR2 dimer formation using the TLR2 transmembrane domain (TMD)-derived peptide, TLR2-p (Fink et al., 2013), ameliorated DSS-induced acute colitis by interfering with Ly6C\(^{hi}\) monocyte activation without affecting monocyte recruitment. Altogether, our data reveal that TLR2 heterodimerization plays a fundamental role in the activation of pathogenic pro-inflammatory Ly6C\(^{hi}\) monocytes in UC and that its inhibition might have therapeutic potential in the treatment of acute gut inflammation.

**Results**

The TLR2 TMD-derived peptide, TLR2-p, inhibits TLR2 signaling by interacting with its reciprocal receptors within the membrane

Hetero- and homodimerization of TLR are critical steps in the activation of these PRRs (Akira & Takeda, 2004; Kaisho & Akira, 2006; Botos et al., 2011; Kang & Lee, 2011; Irvine et al., 2013). To specifically target TLR2 and modulate its activities, we synthesized a peptide derived from the C-terminus of the TLR2 TMD region (TLR2-p) and established that it impaired induced TLR2 signaling in a sepsis model (Fink et al., 2013). To investigate whether interference with TLR2 activation by the TLR2-p peptide is due to peptide–protein interactions within the membrane, we analyzed its co-localization with TLR2 and TLR1 using confocal microscopy. Bone marrow (BM) culture-derived macrophages were probed with an antibody against TLR2, followed by staining with a secondary APC-labeled antibody (Fig 1A) or with an antibody against TLR1, followed by staining with a secondary FITC-labeled antibody (Fig 1B). For membrane staining, cells were labeled with the lipid dye DiD (Fig 1C). The stained cells were then treated with either a rhodamine-labeled TLR2-p peptide or scrambled TLR2 peptide (scrTLR2-p), as control. Merge images revealed that TLR2-p localized to the cell membrane and in the same regions as TLR2 and TLR1, unlike the scrTLR2-p peptide that was found throughout the cell (Fig 1A and B). The co-localization of the TLR2-p with TLR2, TLR1, or the membrane was significantly higher, than with the control peptide.

The specific interaction of the TLR2-p with its native reciprocal TLR was further investigated by co-immunoprecipitation assay. BM macrophage lysates were incubated with either rhodamine-labeled TLR2-p or control peptide and then subjected to immunoprecipitation using specific TLR antibodies bound to protein G beads. Following SDS–PAGE, proteins bound to rhodamine-labeled peptides were detected by a fluorescent scanner (Fig 2A). TLR2-p efficiently precipitated with TLR2, TLR1, and TLR6 displaying preference for the latter, while the scrTLR2-p peptide showed only low interaction. To validate the specificity of TLR2-p peptide co-precipitation with its reciprocal receptor, we probed TLR2-p interactions with TLR4 that does not bind TLR2. TLR2-p showed low affinity to TLR4, similar to the levels observed with the control peptide. TLR2-p peptide was further tested for its inhibitory activity in vitro. Primary murine CD115\(^{+}\) monocytes cells treated with lipoteichoic acid (LTA) (TLR2-6 ligand) and PAM3CSK (TLR1 ligand) expressed reduced levels of the pro-inflammatory cytokines TNF-α and IL-6 following treatment with TLR2-p, while the control peptide showed no inhibition (Fig 2B). The same cells, when treated with LPS (TLR4 ligand), showed no differences in their secreted pro-inflammatory cytokines following treatment with TLR2-p. Collectively, this establishes the specific interaction of the TLR2-p peptide with its corresponding receptors, TLR1, TLR2, and TLR6, and provides critical mechanistic insights into the action of TLR2-p and its potential to block its dimerization and activation (Figs 1 and 2).

**TLR2-p peptide inhibits the dimerization of TLR2 and TLR6, resulting in attenuation of downstream signaling**

To test whether the TLR2-p peptide inhibits TLR2–TLR6 dimerization, we performed a fluorescence resonance energy transfer (FRET) assay using the ImageStreamX imaging flow cytometer. BM macrophages were decorated with anti-TLR6 antibodies conjugated to PE, used as a donor (yellow, middle column) and antibodies against TLR2 followed by staining with a secondary APC-labeled antibody, acting as acceptor (see scheme in Fig 3A). LTA exposure induced an APC-FRET signal, indicating TLR6–TLR2 dimerization. Cells pre-incubated with TLR2-p for half an hour prior to LTA activation showed reduced levels of FRET signal similar to non-stimulated cells (Fig 3B). Note that in accordance with earlier reports, we observed weak association between TLR2 and TLR6 before LTA stimulation (Triantafilou et al., 2006). In contrast, control peptide had no effect on dimerization and showed the same FRET signal as LTA-stimulated cells. To verify that the signal observed was due to direct TLR2–TLR6 interactions, we measured FRET between TLR2 and another surface receptor expressed by macrophages, the surface glycoprotein EMR1 (recognized by the F4/80 antibody). No increase of FRET signal was observed in this setting upon LTA stimulation (Fig 3C). Addition of TLR2-p to BM macrophages also efficiently blocked LTA-induced ERK phosphorylation (Fig 3D). Activation of cells pre-treated with scrTLR2-p was indistinguishable from LTA-stimulated cells. Collectively, these results establish that TLR2-p blocks TLR2 signaling in *in vitro* cultures by inhibiting critical TLR2–TLR6 dimerization following LTA stimulation.

**Inhibition of TLR2 dimerization ameliorates acute colitis**

Signals that emanate from TLR2 after its obligatory pairing with TLR6 or TLR1 are thought to contribute to gut inflammation.
Figure 1. TLR2 inhibitor peptide co-localized with its corresponding TLR.

A–C Representative images of cellular localization of TLR2-p and scrTLR2-p peptides in BM-derived macrophages were observed using confocal microscopy. (A) Cells were probed with anti-TLR2 antibody followed by staining with APC-labeled secondary antibody or (B) with anti-TLR1 antibody followed by staining with FITC-labeled secondary antibody (left panels, red). For membrane staining, cells were labeled with lipid dye, DiD (C). Then, rhodamine-labeled fluorescent peptide was added to the cells (middle panels, green). Merged images are shown in the right panel. Scale bars, 10 μm. The mean Pearson correlation coefficient observed for TLR2-p or scrTLR2-p peptides with TLR2, TLR1, and DiD is presented as mean of two independent experiments ± SEM (***P < 0.001, n = 19–61).
Accordingly, strategies interfering with TLR2 activation improve disease scores in UC animal models, although the exact mechanisms of action and cell types targeted by these regimen remain mostly undefined (Hausmann et al., 2002; Pierik et al., 2006; Toiyama et al., 2006; Heimesaat et al., 2007; Frolova et al., 2008). To investigate the therapeutic potential of TLR2 dimerization inhibition, we tested the effect of TLR2-p in an acute colitis model, in which mice are exposed to an oral dextran sodium sulfate (DSS) regimen (Okayasu et al., 1990). Mice were exposed to DSS-containing drinking water for 7 days, with or without intraperitoneal (IP) injections of TLR2-p.
Figure 3. TLR2-p peptide directly inhibits the dimerization of TLR2 and TLR6 after LTA treatment resulting in reduced levels of ERK1/2 signaling.

A A scheme showing the FRET reaction.

B, C Representative images of cellular interaction between TLR2 and TLR6 (A) and between F4/80 and TLR2 (B) in BM-derived macrophages with the indicated treatments were observed by fluorescence resonance energy transfer (FRET) using ImageStreamX. Scale bars, 10 μm. Cells were incubated with 20 μM of TLR2-p or scrTLR2-p peptide for 0.5 h and then washed and incubated with 500 ng/ml LTA for another 0.5 h at 37°C. Cells were probed with anti-TLR6-PE- or anti-F4/80-PE-conjugated antibody (donor) and anti-TLR2 antibody following by staining with APC-labeled secondary antibody (acceptor). PE intensity (middle panel) and FRET intensity (right panel) were measured via ImageStreamX imaging flow cytometer. The FRET intensity is shown as mean ± SEM of two independent experiments (***P < 0.001, n = 2,579–15,567).

D Representative image of ERK1/2 phosphorylation levels in CD115+ BM monocytes upon LTA exposure. Cells were pre-treated for 0.5 h with 20 μM of TLR2-p peptide, scrTLR2-p peptide or untreated and then washed and incubated with 500 ng/ml LTA for the indicated times. ERK1/2 phosphorylation levels and total ERK1/2 levels were detected by Western blotting. Equal loading was detected by measuring tubulin. Results are representative data of two independent experiments. The band intensity was quantified for p-ERK levels after 15 min of LTA exposure. Results are normalized to tubulin levels and are the mean of two experiments ± SD (***P < 0.001).
Figure 4. TLR2-p inhibitor peptide ameliorated DSS-induced colitis.

A A scheme showing peptide and DSS administration regime.
B Representative colonoscopy images of the indicated treatments (day 7). C57BL mice were treated with 2% of dextran sulfate sodium (DSS) in drinking water for 7 days. An amount of 5 mg/kg of TLR2-p and scrTLR2-p peptides were injected IP every following day from day one.
C A graphical summary of endoscopic colitis grades assessed on day 7 after treated with DSS only, DSS with TLR2-p peptide, DSS with scrTLR2-p peptide, and untreated mice (n = 19, 21, 22 and 19, respectively). Results represent the mean ± SD of three independent experiments (***P < 0.001).
D A graphical summary of changes in body weight (day 6) of the indicated groups. Results are the mean ± SD of two independent experiments (n = 6–8) (***P < 0.001).
E Representative H&E histological images for distal colon section (day 7). Black asterisk indicates large collection of blood in the lumen, arrowheads indicate widespread mucosal collapse and ulceration, and arrows indicate edema in the sub mucosa. Scale bars, 100 μm (lower row) and 1,000 μm (upper row).
F A graphical summary of histological severity score of the indicated treatments. Results are the mean ± SD of two independent experiments (n = 9–10) (**P < 0.01).
every second day (see scheme, Fig 4A). Mice treated with DSS only, or with DSS and the scrambled control peptide (scrTLR2-p), exhibited weight loss and severe colitis, as evaluated by colonoscopy (Becker et al., 2006) (Fig 4B–D). In contrast, TLR2-p-treated mice exhibited significant mitigation in the severity of colitis upon DSS challenge. Moreover, TLR2-p-treated mice also displayed milder mucosal pathology when compared to scrTLR2-p/DSS or DSS only-treated mice, as evidenced by decreased luminal blood and reduced edema and lesion formation (Fig 4E and F). Furthermore, analysis of supernatants of colon explant cultures showed that TLR2-p-treated animals displayed reduced levels of IL-6, IL-1β, and IFN-κ (Fig 5A). The latter finding was supported by results obtained by qRT–PCR analysis of the respective colonic tissue (Fig 5B). Collectively, these results establish that inhibition of TLR2 dimerization by TLR2-p reduces acute inflammation in DSS-challenged animals.

TLR2-p peptide inhibits TLR2 signaling in Ly6C hi monocytes without affecting their recruitment to the inflamed gut

DSS colitis is associated with a massive tissue infiltration of Ly6C hi monocytes that acquire a pronounced pro-inflammatory signature (Zigmond et al., 2012). Ablation or sequestration of Ly6C hi monocytes ameliorates acute colitis establishing these cells or their derivatives as critical drivers of gut inflammation (Zigmond et al., 2012; Getts et al., 2014). Monocyte infiltrates display prominent expression of TLR2 and TLR6 (Zigmond et al., 2012). We therefore reasoned that the TLR2-p regimen might improve the DSS colitis scores by targeting Ly6C hi monocytes and inhibiting their pro-inflammatory response. First, we evaluated colonic monocyte infiltration. With DSS, the frequency of Ly6C hi cells within the total CD11b + pool increased in the colon, corroborating earlier studies (Waddell et al., 2011; Zigmond et al., 2012). Monocyte infiltrates of DSS/TLR2-p- and DSS/scrTLR2-p-treated mice were comparable to non-peptide-treated controls, establishing that TLR2-p does not affect monocyte recruitment (Fig 6A and B). Next, we investigated whether TLR2-p blocks the pro-inflammatory activity of Ly6C hi monocytes. To compensate for in vivo peptide degradation and to increase binding probability of the peptides to Ly6C hi monocytes, we performed an additional injection on day 5 and sorted Ly6C hi monocytes on day 6 of DSS challenge (see scheme, Fig 7A). Also this modified protocol improved colitis scores of DSS-treated animals (Fig 7B). To probe for a direct effect of the TLR2-p on Ly6C hi monocytes, we isolated the latter from the different animal groups (Fig EV1) and subjected the cells to qRT–PCR analysis for IL-6, IL-12p35, and IL-23p19 production. As shown in Fig 7C, TLR2-p treatment significantly impaired monocyte production of pro-inflammatory cytokines. Taken together, this provides a mechanistic explanation for the fact that TLR2-p treatment ameliorates acute colitis development. Specifically, we show that the agent interferes with the TLR2-triggered activation of Ly6C hi monocytes that infiltrate the gut tissue, thereby curbing the pro-inflammatory reaction.
Monocytes have emerged as critical drivers of acute gut inflammation. Here, we show that neutralization of the pro-inflammatory activities of Ly6Chi monocytes by targeting TLR signaling ameliorated DSS-induced acute colitis. Specifically, we used peptide-based interference with specific TLR dimerization to manipulate the differentiation of recruited monocytes. Collectively, we establish the

Discussion

Monocytes have emerged as critical drivers of acute gut inflammation. Here, we show that neutralization of the pro-inflammatory activities of Ly6Chi monocytes by targeting TLR signaling ameliorated DSS-induced acute colitis. Specifically, we used peptide-based interference with specific TLR dimerization to manipulate the differentiation of recruited monocytes. Collectively, we establish the

Figure 6. TLR2 inhibitor peptide does not have an effect on the recruitment of pro-inflammatory monocytes.

A Flow cytometry analysis of colonic lamina propria CD11c+CD11b+Ly6C+MHCII monocytes from steady state and DSS day 7 treated with TLR2 peptide or scrTLR2 peptide, showing comparable monocyte infiltrates into the colitis colon. Plots were pre-gated on live CD45+ cells.

B Graphical summary of monocytes presented as % out of CD11b+ cells. Results are the mean ± SEM of three independent experiments (n = 3 per group).
critical role of TLR2 dimer formation in the local generation of pro-inflammatory cells in acute gut inflammation.

Ly6Chi monocytes entering the healthy colon acquire a non-inflammatory gene expression profile (Zigmond et al., 2012). In contrast, when entering inflamed tissue, the differentiation of these cells into the quiescent, non-inflammatory CX3CR1hi macrophages is blocked and diverted to a distinct fate (Rivollier et al., 2012; Zigmond et al., 2012). Ly6Chi monocytes then respond to the bacterial products they encounter with the production of pro-inflammatory cytokines, such as IL-23 and IL-6 (Zigmond et al., 2012). These effector monocytes actively promoted gut inflammation, as their ablation using an anti-CCR2 regimen (Zigmond et al., 2012), or microparticle-mediated sequestration (Getts et al., 2014) ameliorates DSS colitis.

Given their plasticity and role as macrophage precursors, Ly6Chi monocytes, and their equivalent in the human, the classical CD14- CD16+ monocytes, have emerged as attractive targets for cellular therapy. However, approaches interfering with monocyte recruitment, such as ablation or sequestration, or targeting of critical chemokine receptors (Leuschner et al., 2011), also inherently prevent the re-establishment of non-inflammatory CX3CR1hi macrophages and thus by themselves compromise gut homeostasis. Manipulations that specifically interfere with the local development of pro-inflammatory effector monocytes are hence to be favored. Here, we highlight the potential of such an approach by showing that specific neutralization of TLR2 signaling by inhibiting critical TLR dimerization blocks monocyte differentiation into pro-inflammatory cells.

Figure 7. TLR2-\(p\) inhibitor peptide downregulates pro-inflammatory cytokines expressed by pro-inflammatory monocytes.

A A scheme showing peptide and DSS administration regime.
B Weight loss of DSS-challenged mice on day 6 (***\(P < 0.001\)). Results are the mean ± SD of three independent experiments (\(n = 4–5\)).
C Real-time PCR analysis showing mRNA expression levels of IL-6, IL-12p35, and IL-23p19 of FACS-isolated monocytes collected from mice with the indicated treatments. Results are the mean ± SEM of two to three independent experiments (*\(P < 0.05\), **\(P < 0.01\), \(n = 6–7\) mice pooled per group).
Prevention of colitis as assessed by histology, colonoscopy, and body weight measurements. Whole tissue analysis through colon explant cultures and RT-PCR analysis of these monocyte-derived macrophages (5 × 10⁴) were fixed with 3% paraformaldehyde for 20 min and washed with PBS. The cells were then blocked for unspecific binding with 10% FCS in PBS at room temperature (RT) for 30 min. For labeling of TLR2, mouse anti-TLR2 was added (1:25) overnight at 4°C (Biologend), followed by staining with a secondary anti-mouse-APC (1:100) for 10 min at RT. The Rho-labeled fluorescent peptide (1 μM) was added (1:50) overnight at 4°C (Biolegend), followed by staining with a secondary anti-rat-FITC (1:100) for 2 h at RT (Santa Cruz Biotechnology). For labeling of TLR1, rat anti-TLR1 was added (1:25) overnight at 4°C (Biolegend), followed by staining with a secondary anti-rat-FITC (1:100) for 2 h at RT (Santa Cruz Biotechnology).

Materials and Methods

Peptide synthesis, purification, and fluorescent labeling

TLR2-p peptide (kkLILLVGALALHAFHGWkk) and scrTLR2-p peptide (kkGFGLHRVWLHLLTLckk) were synthesized by a 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase method on Rink amide MBHA resin (Calbiochem-Novabiochem, San Diego, California) by using an ABI 433A automatic peptide synthesizer (Applied Biosystems, Foster City, CA) as described previously (Merrifield et al., 1982). Following, the peptides were cleaved from the resin by incubation for 2 h with 95% TFA, 2.5% H₂O, and 2.5% triethylsilane. Purification of the crude peptides was performed by RP-HPLC (> 98%) on a Vydac C4 column (Grace Discovery Sciences, Deerfield, IL). The cleaning of the peptide was then identified by electrospray mass spectroscopy. For assays with fluorescent peptides, addition of Rho (rhodamine) 5(6)-carboxytetramethylrhodamine N-succinimidyl ester (TAMRA, BioChemika) fluorescent probe to the N-terminus of the peptides was performed by standard Fmoc chemistry. Peptides used for in vivo assay were treated twice with 20% acetic acid for the replacement of the trifluoroacetate anion added during HPLC purification.

Bone marrow macrophage and monocyte isolation

Femora and tibiae BM cells were collected and cultured in RPMI medium containing FBS (10%), L-glutamine (1%), sodium pyruvate (1%), Pen-strep (1%), and 10 ng/ml recombinant CSF-1 (Peprotech). For isolation of CD115+ monocytes, ficoll density gradients were used to remove erythrocytes followed by MACS cell separation with CD115-biotin (AFS998, Biologend) and streptavidin-conjugated magnetic beads (Miltenyi Biotech). At day 3, half the medium was replaced, and on day 7, cells were used for the different in vitro assays.

Co-localization of peptides with TLR molecules and lipid dye

BM-derived macrophages (5 × 10⁴) were fixed with 3% paraformaldehyde for 20 min and washed with PBS. The cells were then blocked for unspecific binding with 10% FCS in PBS at room temperature (RT) for 30 min. For labeling of TLR2, mouse anti-TLR2 was added (1:25) overnight at 4°C (Biolegend), followed by staining with a secondary anti-mouse-APC (1:100) for 2 h at RT (Biolegend). For labeling of TLR1, rat anti-TLR1 was added (1:50) overnight at 4°C (eBioscience), followed by staining with a secondary anti-rat-FITC (1:100) for 2 h at RT (Santa Cruz Biotechnology). For labeling of the membrane, fluorescence lipid dye 1,1'-dioctadecyl-3,3',3',3'-tetramethylindocarbocyanine-5,5'-disulfonic acid, DiD (0.5 μg/ml, Invitrogen) was added for 10 min at RT. The Rho-labeled fluorescent peptide (1 μM) was
added during the last 1 min of incubation. Afterwards, cells were washed with PBS and deposited onto a glass slide using Fluoro-mount-G (Southern Biotech) overnight at RT. The labeled cell samples were observed under a fluorescence confocal microscope, Olympus IX81 FV10-ASW, objective 60× (oil), NA:1.35 (due to color corrected). DiD and TLR2-APC were observed under fluorescence intensity of 560 nm, TLR1-FTTC under fluorescence intensity of 488 nm, and rhodamine-labeled peptides under fluorescence intensity of 560 nm. The levels of co-localization were measured by Pearson correlation coefficient using the Imaris analyzing software (Bitplane).

Immunoprecipitation of fluorescently labeled peptides with TLR

BM-derived macrophages (2 × 10^6) were incubated with 1 μM rhodamine-labeled peptide for 1 h at 37°C. Then, the cells were washed and lysed with ice-cold radio immunoprecipitation (RIPA) assay buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS). After 15 min of centrifugation at 14,000 rpm, 4°C, the supernatants were incubated with TLR antibodies including anti-TLR2, anti-TLR6, anti-TLR1, and anti-TLR4 (Santa Cruz Biotechnology) overnight at 4°C. Following, the samples were added to protein G beads (Santa Cruz Biotechnology) for a second overnight incubation at 4°C. The beads were then washed with cold PBS, diluted 1:2 with SDS tricine buffer, and boiled for 10 min at 95°C. Protein supernatants were subjected to 12% SDS–PAGE and the presence of co-immunoprecipitated peptide was detected with a Typhoon 9400 variable mode imager. Excitation was set at 532 nm and emission at 585 nm. Western blot analysis was performed with a secondary antibody conjugated to HRP. To verify equal loading amount, tubulin was blotted using an anti-tubulin antibody (Santa Cruz Biotechnology).

Fluorescence resonance energy transfer (FRET) between TLR2 and TLR6

BM-derived macrophages (4 × 10^6) were stimulated with 20μM of TLR2-p peptide or scrTLR2-p peptide for 0.5 h at 37°C, washed three times with PBS, and stimulated with 500 ng/ml LTA for 0.5 h at 37°C. Following, cells were fixed with 3.7% paraformaldehyde for 20 min at RT and washed with PBS. The cells were then permeabilized and blocked for unspecific binding with 5% donkey serum, 1 mg/ml BSA, and 0.1% Triton in PBS at RT for 15 min. For labeling of TLR6, rabbit anti-TLR6-PE-conjugated polyclonal antibody was added (1:50) over night at 4°C (Bioss, Inc.) TLR2 staining was performed as described above. For F4/80 labeling, rat anti-F4/80 PE-conjugated monoclonal antibody was added (1:100) for 0.5 h at RT (Serotec). Cells were imaged using multispectral imaging flow cytometry (ImageStreamX Mark II, Amnis Corp), objective 60×, NA:0.9 at RT. Cells in PBS were collected from each sample, and data were analyzed using image analysis software (dedicated software; Amnis Corp). Images were compensated for fluorescent dye overlap by using single-stain controls. Cells were gated for single cells using the area and aspect ratio features, and for focused cells using the Gradient RMS feature, as previously described (George et al, 2006). The instrument is composed of two cameras, which allows separation of the signals—camera 1 for 488-nm and 561-nm lasers (channels 1–6), and camera 2 for the 405-nm and 642-nm lasers (channels 7–12). For FRET measurements, the samples were illuminated with the 488-nm laser. The PE staining was measured on channel 3 (560–595 nm) and the FRET resulting fluorescence was collected on channel 5 (640–745 nm). As a control for staining intensity, the APC staining was also read using the 642-nm laser on channel 11 (640–745). The FRET was calculated for each cell by the FRET intensity. Results are normalized to untreated cells.

Phospho-ERK detection assay

BM-derived macrophages (1 × 10^6) were pre-treated with growing medium containing 0.1% serum overnight. Then, the cells were treated with the peptides for 1 h (20 μM), washed with PBS, and stimulated with LTA at 37°C (500 ng/ml) for the indicated times. Following, this, cell lysates were prepared in RIPA buffer containing 50 mM NaF, 2 mM Na3VO4, protease and phosphatase inhibitors (Sigma-Aldrich). Protein concentration was measured using the BCA Protein Assay Kit (Pierce Chemical Co.), and 50 μg of protein was loaded and separated on 12% SDS–PAGE. Afterwards, the samples were transferred onto PVDF membrane. The immunoblot was incubated overnight with blocking solution (2% BSA in Tris-buffered saline and Tween-20, TBST) at 4°C and then incubated with primary antibodies, phospho-ERK1/2, total-ERK1/2, or tubulin, for 1 h at RT (Sigma). After washing with PBST, HRP-conjugated secondary antibody was applied for 2 h at RT. The blots were developed on an enhanced chemiluminescence (ECL) detection system.

Mice

All animal experiments were approved by the Institutional Animal Care and Use Committee. C57BL/6 mice were purchased from Harlan (Rehovot, Israel). Animals were kept in specific pathogen-free (SPF) environment.

DSS-induced experimental colitis

After 7 days of exposure to 2% DSS in the drinking water, C57 black mice developed colitis. An amount of 5 mg/kg of TLR2 and scrTLR2 peptides dissolved in saline was injected IP every following day from day one. Control C57 black mice were given regular drinking water and injections of saline.

Murine colonoscopy

High-resolution murine video endoscopic system was used to score mice for colitis severity. The system consist a miniature probe (1.9 mm outer diameter), a xenon light source, a triple chip HD camera, and an air pump (“Coloview”, Karl Storz) to achieve regulated inflation of the mouse colon. Windows Movie Maker software (Microsoft) was used to process the digitally recorded video files. Grading of colitis scores was conducted as previously described (Becker et al, 2006).

Histology

Four percent of paraformaldehyde was used to fix the tissues overnight at 4°C, and tissues were embedded in paraffin, sectioned, and...
stained with H and E. Slides were evaluated using an Olympus BX51 microscope, and image acquisition was conducted with the Olympus DP70 camera and DP-Manager software. Grading of histology scores was done by a pathologist and conducted as follows: (i) amount of inflammation: 0—none, 1—mild, 2—moderate, 3—severe, and 4—significant accumulation of inflammatory cells in the gut lumen, (ii) depth of inflammation: 0—none, 1—mucosa or submucosa only, 2—mucosa and submucosa, 3—limited transmural (2.5 in < 20% of inflamed segment), and 4—transmural, (iii) nature of changes: 0—ulcer < 30% of affected mucosa and 1—ulcers > 30% of affected mucosa, (iv) re-epithelialization: if widespread gut lumen, (ii) depth of inflammation: 0.

For the in vitro experiment, 1 × 10⁶ primary CD115⁺ cells were treated with TLR2-p or scrtLR2-p peptide for 2 h at 37°C. Then, the peptide was washed and the cells were stimulated with either LTA or TLR2-p peptide for 2 h at 37°C. Supernatants were collected and kept at -20°C until assessment. Quantitative evaluations of IL-6, IL-1β, and IFN-γ levels in supernatants were done using a Duoset ELISA kit (R&D Systems).

cDNA Synthesis and Real-Time RT-PCR was performed following the method established previously (Aychek et al., 2015).

Real-time RT-PCR primers

The sequences for primers used in this study are as follows:

<table>
<thead>
<tr>
<th>Primers</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6</td>
<td>5’-TCC AAT GCT CTC CTA ACA GAT AAG-3’</td>
<td>5’-CAAT GCA TTG GAT GGT CTG G-3’</td>
</tr>
<tr>
<td>IL-23p19</td>
<td>5’-GGT GGC TCA GGG AAA TGT-3’</td>
<td>5’-GAC AGA GCA GCC AAG TAC AG-3’</td>
</tr>
<tr>
<td>IL-12p35</td>
<td>5’-GCC ACC CTT GCC CTC GTA A-3’</td>
<td>5’-GGT TG GTC CCG TGT GAT GTC-3’</td>
</tr>
<tr>
<td>TBP</td>
<td>5’-GAA GCT GCG GTA CAA TTC CAG-3’</td>
<td>5’-CCC CTT GTA CCC TTC ACC AAT-3’</td>
</tr>
</tbody>
</table>

Statistical analysis

Samples sizes were chosen with adequate statistical power on the basis of past experience and literature. Differences between group means were tested with a t-test when the experiment contained two groups, or one-way ANOVA (followed by a Tukey post hoc test) when the experiment contained more than two groups. In cases where the experiment was run in two batches, “batch” was entered as a random categorical factor into a 2-way ANOVA. Residuals were tested for normal distribution using Shapiro–Wilk tests, and homogeneity of variances was tested using Levenes’ tests or F-test where only two variances were compared. Analysis were done using STATISTICA (data analysis software system), version 12 StatSoft, Inc. All exclusion/inclusion criteria were pre-established according to the IACUC. The colonoscopy and histology experiments were performed with blinding of the investigators. Data are presented as mean ± SEM. Values of P < 0.05 were considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0005.

Expanded View for this article is available online.

Acknowledgements

We would like to thank Dr. Udi Zigmond, Dr. Dan Blat, and Ran Afik for their help in the colonoscopy, Dr. Muhammad (Mody) Ali for assistance with in vivo experiments, Vladimir Kiss for technical assistance with the confocal imaging, Dr. Reinit Nevo for help with colonoscopy analysis, and Dr. Ron Rotkopt for performing the statistic. We also thank Dr. Eliran M. Reuven for technical assistance in experiments and Dr. Ron Saar Dover and Yoel A. Klug for insightful discussions and critical revision of the manuscript. Yeichiel Shai is the incumbent of the Harold S. and Harriet B. Brady Professorial Chair in Cancer Research. This study was supported in part by the Helmsley Trust grant, the Israel Science Foundation, grant No. 1409/12 (YS), Pasteur Weizmann Foundation, and the European Research Council, grant No. 340345 (S.J.).

Author contributions

LS-G and TA conceived the study, designed, and performed experiments, and analyzed data; AF conceived the study and designed the peptides; ZP directed and analyzed the FRET experiments; BZ provided critical reagents and analyzed data; BB performed the in vitro experiments; OB interpreted histology; YS and SJ directed the project; and LS-G, TA, SJ, and YS wrote the paper.

Conflict of interest

The authors declare that they have no conflict of interest.

References


The EMBO Journal Vol 35 | No 6 | 2016
© 2016 The Authors


